Intercept Pharmaceuticals   Report issue

Contributed to NME For profit Phase 2 Phase 4
Founded: New York NY United States (2002)

Organization Overview

First Clinical Trial
2007
NCT00501592
First Marketed Drug
2016
obeticholic acid (ocaliva)
First NDA Approval
2016
obeticholic acid (ocaliva)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Intercept Pharmaceticals, Inc. | Intercept Pharmaceuticals | Intercept Pharmaceuticals - Chief Medical Officer | Intercept Pharmaceuticals, Inc. | Intercept Pharmaceuticals, San Diego, CA 92122 | INTERCEPT PHARMS INC

Active Ingredients

Marketed Drugs (1)

obeticholic acid (ocaliva) (2016 NDA)

Drugs in Phase 4 Trials (1)

obeticholic acid (ocaliva) (18 trials)

Drugs in Phase 2 Trials (4)

atorvastatin (lipitor) (1 trial)

bezafibrate (Bezalip) (1 trial)

int-787 (1 trial)

ursodeoxycholic acid (1 trial)

Indications

Approved Indications


 

Liver Cirrhosis, Biliary

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholangitis (Phase 4)

Cholangitis, Sclerosing (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Fatty Liver (Phase 3)

Fibrosis (Phase 4)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis, Alcoholic (Phase 2)

Liver Cirrhosis (Phase 4)

Liver Cirrhosis, Biliary (Phase 4)

Liver Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 5